Filing Flows › Onconetix (ONCO) › Q1 2025
Onconetix (ONCO) Q1 2025 earnings results (first quarter 2025)
10-Q filed Jun 12, 2025
Onconetix (ONCO) reported revenue of $102K for the first quarter 2025 (Q1 2025), -85% from a year earlier and -86% from the quarter before.
Onconetix, Q1 2025: revenue $102K (-86% year over year), net loss $8.5M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $102K | -86% | -85% |
| Operating profit | −$12.6M | — | — |
| Net earnings | −$8.5M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $102K in Q1 2025, down 85% year over year and down 86% from the previous quarter. Product Sales was the largest line at 99% of revenue. development Services lost $621K year over year (down 100%), 104% of the total change.
Gross margin was 45.1%, up 18.1 points from a year earlier. Operating costs exceeded revenue by $12.6M, an operating margin of -12369.2%. Operating expenses grew 12% against a revenue fall of 85%. The fastest-growing cost line was Other operating costs (+46%). The quarter ended with a net loss of $8.5M, narrower than the previous quarter's $29.4M loss. Non-operating items added $4.0M, -47% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.0M. Non-cash charges added back $5K of depreciation and amortization and $29K of share-based compensation. Working capital and other items added $6.5M.
Questions
What was Onconetix's revenue in the first quarter 2025?
Onconetix (ONCO) reported revenue of $102K for the first quarter 2025 (Q1 2025), -85% from a year earlier and -86% from the quarter before.
Source: Onconetix 10-Q on SEC EDGAR.